2-Cl-IB-MECA - Moligand™, ≥98%(HPLC) , Adenosine A3 receptor agonist, CAS No.163042-96-4, Adenosine A3 receptor agonist

CAS: 163042-96-4 Cat. No.: C133243 Summenformel: C18H18ClIN6O4 Molekulargewicht: 544.73 EG-Nummer: 634-077-2
Zu bestellen verfügbar
QUALITÄT & REINHEIT Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. ≥98%(HPLC)
Synonyms
2-Cl-IB-Meca|2Cl-IB-MECA|(2S,3S,4R,5R)-5-(2-Chloro-6-((3-iodobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxy-N-methyltetrahydrofuran-2-carboxamide|Namodenoson (CF-102)|Namodenoson [USAN]|(2S,3S,4R,5R)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide|2-chloro-N6-(3-iodobenzyl)adenosine-5-N-methylcarboxamide|(2S,3S,4R,5R)-5-(6-(3-iodobenzylamino)-2-chloro-9H-purin-9-yl)-3,4-dihydroxy-N-methyl-tetrahydrofuran-2-carboxamide|beta-D-Ribofuranuronamide, 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-|1-[2-CHLORO-6-[[(3-IODOPHENYL)METHYL]AMINO]-9H-PURIN-9-YL]-1-DEOXY-N-METHYL-BETA-D-RIBOFURANURONAMIDE|Cl-IB-MECA|1-[2-Chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-beta-D-ribofuranuronamide;2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide;2-Cl-IB-MECA;2-Cl-IB-MECA|2-Chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide|CI-IB-MECA|NAMODENOSON [WHO-DD]|.BETA.-D-RIBOFURANURONAMIDE, 1-(2-CHLORO-6-(((3-IODOPHENYL)METHYL)AMINO)-9H-PURIN-9-YL)-1-DEOXY-N-METHYL-|CF-102;2-Cl-IB-MECA|1-(2-Chloro-6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-1-deoxy-N-methyl-beta-D-Ribofuranuronamide|C1-IB-MECA|Namodenoson|Chloro-IB-MECA|Namodenoson (USAN/INN)|(2S,3S,4R,5R)-5-(2-chloro-6-(3-iodobenzylamino)-9H-purin-9-yl)-3,4-dihydroxy-N-methyltetrahydrofuran-2-carboxamide|CF 102|CF102|CF-102|CF-102(2-Cl-IB-MECA)|2-Chloro-N(6)-(3-iodobenzyl)-9-(5-(methylcarbamoyl)-beta-D-ribofuranosyl)adenine|NAMODENOSON [INN]|1-(2-CHLORO-6-(((3-IODOPHENYL)METHYL)AMINO)-9H-PURIN-9-YL)-1-DEOXY-N-METHYL-.BETA.-D-RIBOFURANURONAMIDE|(2S,3S,4R,5R)-5-(2-chloro-6-{[(3-iodophenyl)methyl]amino}-9H-purin-9-yl)-3,4-dihydroxy-N-methyloxolane-2-carboxamide|2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide|beta-D-Ribofuranuronamide, 1-(2-chloro-6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-1-deoxy-N-methyl-
Storage
Protected from light,Store at -20°C
Shipped In
Ice chest + Ice pads
★
Größe
Deutschland (EU)
USA*
Preis
Menge
5mg
C133243-5mg
—
2 Auf Lager

25,08€

38,09€
Speichern 13,02 € (34.17%)
10mg
C133243-10mg
—
1 Auf Lager

44,17€

66,73€
Speichern 22,56 € (33.81%)
25mg
C133243-25mg
—
2 Auf Lager

96,23€

144,83€
Speichern 48,59 € (33.55%)
50mg
C133243-50mg
—
2 Auf Lager

173,46€

260,23€
Speichern 86,77 € (33.34%)
100mg
C133243-100mg
—
2 Auf Lager

312,30€

468,49€
Speichern 156,19 € (33.34%)
250mg
C133243-250mg
Auf Bestellung · 8–12 Wochen

682,82€

1.024,71€
Speichern 341,89 € (33.36%)
1g
C133243-1g
Auf Bestellung · 8–12 Wochen

2.183,14€

3.274,76€
Speichern 1.091,62 € (33.33%)
Enter a quantity for the sizes you want to add.

Übersicht

An adenosine analog that acts as a highly selective agonist of adenosine A3 receptor (Ki = 330 pM, 820 nM, 470 nM for A3, A1 and A2A, respectively). Shown to reduce ischemia reperfusion injury in mice and limit infarct size in isolated rat hearts. Shown to reversibly increase field excitatory postsynaptic potentials in hippocampal slices and exhibits excitatory effects on both evoked and spontaneous epileptiform discharges.

A highly selective agonist of adenosine A3 receptor (Ki = 330 pM)

Spezifikationen

Synonyme
2-Cl-IB-Meca | 2Cl-IB-MECA | (2S,3S,4R,5R)-5-(2-Chloro-6-((3-iodobenzyl)amino)-9H-purin-9-yl)-3,4-dihydroxy-N-methyltetrahydrofuran-2-carboxamide | Namodenoson (CF-102) | Namodenoson [USAN] | (2S,3S,4R,5R)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide | 2-chloro-N6-(3-iodobenzyl)adenosine Show more
Spezifikationen & Reinheit
Moligand™, ≥98%(HPLC)
Biochemische und physiologische Mechanismen
High affinity and extremely selective A3adenosine receptor agonist (Ki= 0.33 nM). Displays 2500- and 1400-fold selectivity over A1and A2Areceptors respectively. Exhibits high selectivity over the Na+-independent adenosine transporter.
Storage
Protected from light,Store at -20°C
Verschickt in
Ice chest + Ice pads
Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.
Note
Moligand™
Aktionsart
AGONIST
Mechanismus der Wirkung
Adenosine A3 receptor agonist
Reinheit
≥98%(HPLC)
Produkteigenschaften
ALogP
1.9
Namen und Kennungen
Pubchem Sid
Pubchem Sid Url
https://pubchem.ncbi.nlm.nih.gov/substance/504762364
SMILES
CNC(=O)C1C(C(C(O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O
IUPAC Name
(2S,3S,4R,5R)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide
InChIKey
IPSYPUKKXMNCNQ-PFHKOEEOSA-N
InChI
1S/C18H18ClIN6O4/c1-21-16(29)13-11(27)12(28)17(30-13)26-7-23-10-14(24-18(19)25-15(10)26)22-6-8-3-2-4-9(20)5-8/h2-5,7,11-13,17,27-28H,6H2,1H3,(H,21,29)(H,22,24,25)/t11-,12+,13-,17+/m0/s1
Isomere SMILES
CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O
WGK Deutschland
3
Molekulargewicht
544.73
Reaxy-Rn
24720887
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=24720887&ln=

Erweiterte Daten

Taxonomic Classification

Taxonomy Tree

KingdomOrganic compounds
SuperclassNucleosides, nucleotides, and analogues
KlassePurine nucleosides
SubclassNot available
Intermediate Tree Nodes Not available
Direct ParentPurine nucleosides
Alternative Parents Glycosylamines  6-alkylaminopurines  Benzylamines  Secondary alkylarylamines  Aminopyrimidines and derivatives  Iodobenzenes  2-halopyrimidines  Aryl iodides  Aryl chlorides  Imidolactams  N-substituted imidazoles  Tetrahydrofurans  Heteroaromatic compounds  Secondary alcohols  Secondary carboxylic acid amides  Amino acids and derivatives  1,2-diols  Oxacyclic compounds  Azacyclic compounds  Carbonyl compounds  Hydrocarbon derivatives  Organic oxides  Organochlorides  Organoiodides  Organopnictogen compounds  
Molecular FrameworkAromatic heteropolycyclic compounds
Substituents Purine nucleoside - Glycosyl compound - N-glycosyl compound - 6-alkylaminopurine - 6-aminopurine - Imidazopyrimidine - Purine - Benzylamine - Aminopyrimidine - Halobenzene - Halopyrimidine - 2-halopyrimidine - Iodobenzene - Secondary aliphatic/aromatic amine - Aryl chloride - Aryl halide - Aryl iodide - Monocyclic benzene moiety - Imidolactam - Benzenoid - N-substituted imidazole - Pyrimidine - Tetrahydrofuran - Azole - Heteroaromatic compound - Imidazole - Secondary carboxylic acid amide - Secondary alcohol - 1,2-diol - Carboxamide group - Amino acid or derivatives - Secondary amine - Oxacycle - Azacycle - Carboxylic acid derivative - Organoheterocyclic compound - Carbonyl group - Amine - Organohalogen compound - Alcohol - Organic nitrogen compound - Organooxygen compound - Organic oxide - Hydrocarbon derivative - Organoiodide - Organochloride - Organic oxygen compound - Organopnictogen compound - Organonitrogen compound - Aromatic heteropolycyclic compound
BeschreibungThis compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.
External Descriptors Not available
3D-Struktur
Interaktives chemisches Strukturmodell





Zugehörige Ziele (menschlich)
ADORA2A Tclin Adenosine receptor A2a (3 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
ADORA2B Tclin Adenosine receptor A2b (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
ADORA1 Tclin Adenosine receptor A1 (5 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
ADORA3 Tchem Adenosine receptor A3 (48 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PPARD Tchem Peroxisome proliferator-activated receptor delta (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PPARG Tclin Peroxisome proliferator-activated receptor gamma (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
NR3C1 Tclin Glucocorticoid receptor (14987 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR1A Tclin Serotonin 1a (5-HT1a) receptor (14969 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR1D Tclin Serotonin 1d (5-HT1d) receptor (2897 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR1B Tclin Serotonin 1b (5-HT1b) receptor (2801 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR2A Tclin Serotonin 2a (5-HT2a) receptor (14758 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR2C Tclin Serotonin 2c (5-HT2c) receptor (11471 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADORA1 Tclin Adenosine A1 receptor (17603 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PPARG Tclin Peroxisome proliferator-activated receptor gamma (15191 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR3A Tclin Serotonin 3a (5-HT3a) receptor (3366 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PPARA Tclin Peroxisome proliferator-activated receptor alpha (9197 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR4 Tclin Serotonin 4 (5-HT4) receptor (2068 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC29A1 Tclin Equilibrative nucleoside transporter 1 (1711 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR2B Tclin Serotonin 2b (5-HT2b) receptor (10323 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADORA2A Tclin Adenosine A2a receptor (16305 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADORA2B Tclin Adenosine A2b receptor (7672 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADORA3 Tchem Adenosine A3 receptor (15931 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR1E Tchem Serotonin 1e (5-HT1e) receptor (696 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR5A Tchem Serotonin 5a (5-HT5a) receptor (1433 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR6 Tchem Serotonin 6 (5-HT6) receptor (9749 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NR1H3 Tchem LXR-alpha (2891 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SMPD1 Tchem Sphingomyelin phosphodiesterase (13561 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PIN1 Tchem Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (36611 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NR1H2 Tchem LXR-beta (3841 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ABCG2 Tchem ATP-binding cassette sub-family G member 2 (4927 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TDP1 Tchem Tyrosyl-DNA phosphodiesterase 1 (345557 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GMNN Tbio Geminin (128009 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ATAD5 Tbio ATPase family AAA domain-containing protein 5 (122566 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
RGS4 Tchem Regulator of G-protein signaling 4 (13867 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CDK5 Tchem Cyclin-dependent kinase 5/CDK5 activator 1 (3697 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADORA1 Tclin Adenosine receptors; A1 & A3 (1051 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADORA3 Tchem Adenosine receptors; A2a & A3 (373 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TARDBP Tchem TAR DNA-binding protein 43 (40113 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Zugehörige Ziele (nicht menschlich)
Htr7 Serotonin 7 (5-HT7) receptor (19 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Ppard Peroxisome proliferator-activated receptor delta (358 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hdac6 Histone deacetylase 6 (222 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasmodium falciparum (966862 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rep Replicase polyprotein 1ab (378 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Nfe2l2 Nuclear factor erythroid 2-related factor 2 (214 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FTL Ferritin light chain (43324 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Adora1 Adenosine receptors; A1 & A2a (368 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Adora2a Adenosine receptor A2a and A3 (172 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Wirkungsmechanismen
Zertifikate (CoA, COO, BSE/TSE und Analyse-Diagramm)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

9 results found

Lot NumberCertificate TypeDatumArtikel
K2510052K2510052Certificate of AnalysisNov 20, 2025 C133243
J2515084J2515084Certificate of AnalysisOct 28, 2025 C133243
A2219319A2219319Certificate of AnalysisAug 11, 2025 C133243
A2219324A2219324Certificate of AnalysisAug 11, 2025 C133243
A2219342A2219342Certificate of AnalysisAug 11, 2025 C133243
A2219352A2219352Certificate of AnalysisAug 11, 2025 C133243
A2219382A2219382Certificate of AnalysisAug 11, 2025 C133243
A2219383A2219383Certificate of AnalysisAug 11, 2025 C133243
A2219390A2219390Certificate of AnalysisAug 11, 2025 C133243
Chemische und physikalische Eigenschaften
LöslichkeitSolvent:DMSO, Max Conc. mg/mL: None, Max Conc. mM: 100
Empfindlichkeitlight & heat sensitive
Schmelzpunkt (°C)207.0 to 211.0 °C
Molekulargewicht544.700 g/mol
XLogP31.900
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count8
Rotatable Bond Count5
Exact Mass544.012 Da
Monoisotopic Mass544.012 Da
Topological Polar Surface Area134.000 Ų
Heavy Atom Count30
Formal Charge0
Complexity623.000
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
The total count of all stereochemical bonds0
Covalently-Bonded Unit Count1
Lösungsrechner
Bewertungen

Kundenbewertungen

Application Protocols

Item-specific, validated protocols are not provided in the Product Data. The following are general, literature-based guidelines for using adenosine A3 receptor agonists in research. Adjust to your system and consult the SDS/CoA.

  • Stock preparation:

    • Dissolve the solid in anhydrous DMSO to 10–50 mM (literature typical range), vortex and, if needed, sonicate briefly under subdued light. Aliquot into amber vials and store at −20 °C.
  • Cell-based agonism assay (general outline):

    1. Seed A3AR-expressing cells in 96-well plates; incubate overnight.
    2. Prepare serial dilutions in assay buffer ensuring final DMSO ≤0.1–0.5%.
    3. Preincubate cells with phosphodiesterase inhibitor if measuring cAMP.
    4. Add ligand and incubate 15–60 min at 37 °C.
    5. Quantify readout (e.g., cAMP, ERK phosphorylation) per kit instructions.
  • Membrane binding (radioligand displacement; general):

    • Buffer: Tris or HEPES with MgCl2; include 0.1% BSA to reduce nonspecific binding.
    • Incubate membranes with a known A3AR radioligand and serial dilutions of test compound; separate bound/free by filtration; analyze Ki via non-linear regression.
  • Analytical standard preparation:

    • Prepare 1 mg/mL in MeOH or 50:50 MeOH/H2O; store at −20 °C protected from light; verify stability by periodic LC–MS.

All procedures are for research use only.

Biological Roles
  • Functional class (literature): Potent, selective agonist of the adenosine A3 receptor (A3AR), a Gi/o‑coupled GPCR. The “2‑Cl‑IB‑MECA” scaffold incorporates modifications (2‑chloro on purine, 3‑iodobenzyl at N6, and 5′‑N‑methyluronamide) known to enhance A3AR affinity and selectivity relative to A1/A2A subtypes.

  • Mechanistic notes (general, not item-specific claims):

    • A3AR activation typically inhibits adenylyl cyclase, reducing intracellular cAMP; additional downstream effects can include modulation of MAPK/PI3K pathways depending on cell context.
    • Nucleoside transporters and adenosine deaminase do not efficiently process many N6‑benzyl, 2‑halogenated analogs, which can prolong effective exposure in cell-based systems (literature observation for this chemical class).
  • Typical research uses:

    • Tool compound to dissect A3AR-mediated signaling, receptor reserve, and biased agonism.
    • Benchmark control in antagonist/agonist panels for receptor profiling.
    • Pharmacological validation in recombinant overexpression systems and native tissues expressing A3AR.
  • Selectivity considerations (literature):

    • The N6‑arylmethyl plus 5′‑uronamide pattern confers higher A3AR potency while reducing activity at A1/A2A; nonetheless, off-target interactions and species differences can occur—verify with orthogonal assays.
  • Note: All uses are for research only. No medical or clinical claims are made.

Buffer Applications

This compound is not a buffering agent. However, it is commonly prepared and used in biological buffers for receptor assays.

  • Practical guidance (general, not item-specific specs):

    • Stock solutions: Prepare in DMSO, then dilute into assay buffer (e.g., HEPES- or PBS-based, pH 7.2–7.4) keeping final DMSO ≤0.1–1% v/v.
    • Binding assays: Use Tris, HEPES, or KRH buffers supplemented with Mg2+/Ca2+ as required by receptor systems; include BSA (0.1–0.5%) to reduce nonspecific binding if compatible.
    • Stability: Protect working buffers from light (amber tubes/foil) and keep on ice during extended assays.
  • Filtration: 0.22 μm filtration of working solutions can remove particulates; pre-wet filters with buffer containing the same DMSO percentage to minimize adsorption.

  • Compatibility: Avoid strong acids/bases that can degrade nucleosides; maintain neutral pH to preserve integrity during experiments.

Green Alternatives

For this bioactive ligand, the main environmental consideration is solvent choice for solution preparation and analytical work rather than replacing the molecule itself.

  • Greener solvent strategies (general guidance):

    • Prefer water-rich vehicles with minimal DMSO (≤0.1–1% v/v) when assay tolerance allows.
    • If an aprotic polar solvent is required, dimethyl sulfone or propylene carbonate can sometimes substitute DMF/ACN; however, compatibility with biological systems must be validated.
    • For chromatography, ethanol or isopropanol modifiers can partially replace acetonitrile in some LC methods; expect changes in selectivity/viscosity.
  • Comparison (general, not item-specific specs):

    • DMSO vs DMF: DMSO is less volatile/toxic than DMF and commonly accepted in cell assays, but higher viscosity; both are effective solubilizers.
    • MeOH/EtOH vs ACN: Alcohols are greener but can alter retention and ionization; optimize gradients and buffer strength accordingly.
  • Operational improvements:

    • Prepare higher-concentration master stocks to minimize solvent volume in assays.
    • Use amber glass to extend solution life and reduce waste from photodegradation.
    • Adopt microscale assay formats to reduce solvent usage without compromising data quality.
Pharmaceutical Uses

No therapeutic or clinical use is claimed for this catalog item. The following describes research/formulation roles only.

  • Research/formulation roles (general):

    • Reference standard for analytical method development and QC of adenosine A3 receptor agonist scaffolds (e.g., calibration curves in LC–MS/LC–UV).
    • Positive-control agonist in receptor pharmacology panels for discovery screening.
    • Stability studies: benchmarking degradation pathways (hydrolysis, photolysis) of halogenated nucleoside analogs under ICH-like stress conditions in a research setting.
  • Pharmacopeial status: Not specified for this item; refer to CoA/Spec Sheet.

  • Excipients/compatibility (general considerations):

    • Solubilization via co-solvents (DMSO, ethanol) followed by dilution into isotonic vehicles for in vitro dosing studies.
    • Adsorptive losses may occur on plastics due to the aryl/halogen content; consider low-binding polypropylene or glassware.
  • Note: For any regulated application, qualification of identity, purity, and stability must be established with your internal procedures and the specific CoA for the lot in use.

Physical Properties
  • Item-specific values: Not specified for this item; refer to CoA/Spec Sheet.

  • Practical appearance/phase (item-specific): Not specified for this item; refer to CoA/Spec Sheet.

  • Solubility guidance (general/literature, not a specification):

    • Highly polar, hydrogen-bonding nucleoside analog; typically soluble in high-polarity aprotic solvents such as DMSO and DMF at millimolar concentrations.
    • Aqueous solubility is often low to modest for the neutral free base; co-solvents (≤1–2% DMSO) and gentle warming/sonication can aid dissolution for assay buffers.
    • Salts (if available) may improve water solubility (not specified for this item).
  • Other literature properties (indicative only, not item-specific specs):

    • Expected to be a solid at room temperature (nucleoside analog with multiple heteroatoms and aromatic rings).
    • LogP/logD: low to moderate due to sugar/amide functionality; ionization minimal in physiological pH range aside from amide (non-ionizing) and heterocycle tautomers.
  • Refractive index, pKa, melting point, density, UV–Vis: Not specified for this item; refer to CoA/Spec Sheet. If needed for method development, consult primary literature for 2‑Cl‑IB‑MECA or request the Aladdin CoA.

Quality and Grades
  • Grade: Moligand™

    • Aladdin’s Moligand™ line designates bioactive small molecules/ligands supplied for research and screening. Emphasis is placed on identity and purity suitable for biochemical assays, receptor binding studies, and as analytical reference materials.
  • What this means for this item:

    • Identity confirmation typically via orthogonal methods (e.g., NMR/HRMS/LC–MS). Specific methods/acceptance criteria for this lot: Not specified for this item; refer to CoA/Spec Sheet.
    • Purity level and allowable related substances: Not specified for this item; refer to CoA/Spec Sheet.
    • Residual solvents/inorganics, water content, and assay: Not specified for this item; refer to CoA/Spec Sheet.
  • Stabilizers/format: Not specified for this item; refer to CoA/Spec Sheet. No stabilizer is implied unless stated.

  • Use-case suitability (general guidance):

    • Fit for receptor pharmacology, target validation, cell-based signaling studies, and as a chromatographic reference. For regulated workflows, verify against your method suitability and request a detailed Spec/CoA.
Reaction and Applications

This compound is primarily a bioactive research ligand rather than a synthetic reagent. Accordingly, its most relevant “applications” are biochemical/analytical rather than chemical transformations.

  • Biochemical/analytical applications (literature guidance):

    • Selective activation/probing of adenosine A3 receptors (A3AR) in cell-based assays and membrane preparations.
    • Reference standard for LC–MS/LC–UV quantification in pharmacology workflows and receptor occupancy studies.
    • Competitive binding assays (radioligand displacement) and second-messenger readouts (e.g., cAMP modulation) in engineered cell lines expressing A3AR.
  • Not typically used for synthetic reactions. If derivatization is required (probe development), typical transformations target:

    • Aryl iodide handle for cross-coupling (e.g., Suzuki, Sonogashira) to install reporter tags; care is needed to protect the nucleoside functionality and avoid glycosidic bond cleavage.
    • Amide/sugar protection strategies mirror those for adenosine chemistry (literature: silyl protection on ribose, transient base protection at N6 during coupling steps).
  • Practical handling tips:

    • Maintain low light exposure to minimize potential halogen-mediated photochemistry.
    • Use dry, oxygen-free solvents for sensitive coupling steps; monitor by LC–MS due to the heavy-atom isotope patterns (I, Cl) that aid identification.
Reaction Conditions

This product is not typically used to drive chemical reactions; therefore, there are no standardized “reaction conditions” specific to it. For researchers intending to derivatize it (probe synthesis), the following general, literature-based conditions may be relevant:

  • Cross-coupling on the 3‑iodobenzyl aryl iodide:

    • Suzuki–Miyaura: Pd(0/II) catalysts (e.g., Pd(PPh3)4 or Pd(dppf)Cl2), bases such as K2CO3/Cs2CO3, aqueous dioxane/THF/DMF mixtures, 25–80 °C; protect ribose hydroxyls if necessary.
    • Sonogashira: Pd/Cu co-catalysis (e.g., PdCl2(PPh3)2/CuI), amine base (Et3N/DIPEA), DMF or DMSO, room temp to 60 °C under inert gas.
  • Stability considerations during any transformation:

    • Avoid strong mineral acids and prolonged heating which risk glycosidic cleavage and amide hydrolysis.
    • Protect from light to limit dehalogenation/photolysis.
  • Assay preparation (biological use; not a chemical reaction):

    • Stock in DMSO (millimolar), dilute into neutral buffer, equilibrate 15–30 min at 37 °C for receptor studies; maintain final solvent below assay tolerance. These are general literature practices and not item-specific specifications.
Safety and Handling
  • GHS/Regulatory (item-specific):

    • Signal word: Not specified for this item; refer to SDS.
    • H‑statements/Pictograms/Classification: Not specified for this item; refer to SDS.
  • General laboratory precautions (good practice for halogenated nucleoside analogs; consult SDS for authoritative guidance):

    • PPE: lab coat, nitrile gloves, safety glasses. Handle powders in a fume hood or ventilated enclosure to avoid dust/aerosol inhalation.
    • Avoid skin/eye contact; wash thoroughly after handling. Prevent ingestion and inhalation.
    • Light sensitivity: Product Data specifies “Protected from light” — minimize exposure during weighing and solution prep (use amber glassware or foil wrap).
    • Thermal sensitivity: Avoid elevated temperatures; prepare solutions at ambient temperatures unless necessary.
    • Incompatibilities: Strong oxidizers and strong acids/bases may degrade nucleoside analogs and iodinated aromatics; avoid sodium/halogen exchange conditions unless intended.
    • Spill/accident response: Collect solids by gentle sweeping with minimal dust generation; for solutions, absorb with inert material. Dispose in accordance with institutional and local regulations.
    • First aid (overview): If on skin/eyes, rinse with water for ≥15 min; if inhaled, move to fresh air; if ingested, seek medical advice. Always defer to SDS/site-specific protocols.
  • Waste: Treat as halogenated organic waste. Do not discharge to drains.

Solvent Selection
  • Polarity/solvent class (general): A polar, multifunctional nucleoside analog with limited nonpolar character due to sugar and amide groups; dissolves best in strong H‑bond accepting, high-dielectric solvents.

  • Recommended solvents for stock solutions (literature guidance; not item-specific specs):

    • DMSO: typically supports 10–50 mM stocks for many adenosine analogs; filter-sterilizable; mix into aqueous buffers to final ≤0.1–1% v/v to limit DMSO effects in bioassays.
    • DMF: alternative to DMSO when viscosity or DMSO reactivity is a concern; similar solubilization power.
    • Aqueous buffers: direct dissolution may be limited; consider co-solvent (1–5% DMSO or DMF) and gentle warming (≤37 °C) with sonication.
    • Alcohols (MeOH, EtOH): moderate solubility; useful for analytical standard preparation; verify assay compatibility.
  • Practical tips:

    • Prepare concentrated DMSO stocks under subdued light, aliquot into amber vials, and store at −20 °C per item storage guidance. Avoid repeated freeze–thaw.
    • For LC–MS standards, 50:50 MeOH/H2O or ACN/H2O with 0.1% formic acid improves handling and peak shape; validate for your method.
  • When to choose alternatives:

    • If water-only systems are mandatory, consider forming a salt (if applicable) or using cyclodextrin inclusion or serum-containing media to enhance apparent solubility (general strategies; not item-specific).
Storage and Reconstitution
  • Item-specific storage (from Product Data):

    • Store at −20 °C.
    • Protect from light.
    • Shipped in: Ice chest + ice pads.
  • Container/packaging recommendations (best practice):

    • Keep in amber glass vials or wrap containers in aluminum foil to minimize light exposure.
    • Ensure desiccation if applicable; avoid moisture ingress.
  • Reconstitution (general guidance; not item-specific specs):

    • For stock solutions, dissolve in anhydrous DMSO under subdued light to the desired concentration (e.g., 10–50 mM typical for bioassays). Mix by vortex; brief sonication may assist.
    • Sterile-filter (0.22 μm) if solutions will contact cell cultures. Aliquot into small volumes to avoid repeated freeze–thaw cycles.
  • Stability/use:

    • Store aliquots at −20 °C, protected from light. Allow to equilibrate to room temperature before opening to prevent condensation.
    • Aim to use thawed aliquots within a few weeks; discard if precipitation, discoloration, or unexpected LC–MS profile is observed (general precaution).
  • Compatibility:

    • Avoid strong acids/bases and prolonged heating; maintain neutral pH upon dilution into buffers.
  • Note: For definitive shelf life, purity, and assay data, refer to the lot-specific CoA/Spec Sheet.

Structure and Identity

A high-affinity small-molecule adenosine A3 receptor agonist analog supplied under Aladdin’s Moligand™ line.

  • Item-specific identifiers (from Product Data):

    • SKU: C133243
    • Product Name: 2-Cl-IB-MECA
    • CAS: 163042-96-4
    • PubChem CID: 3035850
    • InChIKey: 147288 (as provided)
    • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Structural class and features (general/literature description, not item-specific specs):

    • Core scaffold: adenosine nucleoside framework (ribofuranose linked to a substituted adenine/purine base).
    • Key substitutions: N6–benzyl substitution bearing an iodo substituent on the aryl ring; a 2-chloro substitution on the purine ring; and a 5′-uronamide bearing N‑methyl (MECA = N‑methylcarboxamido) functionality.
    • Functional groups: purine heterocycle (diaza bicyclic ring), secondary/tertiary amide (uronamide), benzylic linker, aryl iodide, aryl chloride, multiple hydrogen-bond donors/acceptors and a ribose hemiacetal.
    • Stereochemistry: D‑ribofuranose with defined stereocenters at C1′–C4′ (literature: β‑N9‑glycosidic linkage typical of adenosine analogs).
  • 2D description in words (general): ribofuranose ring (five-membered) tethered via an N9 glycosidic bond to a 2‑chloro‑6‑substituted purine; the N6 substituent is a 3‑iodobenzyl moiety; the ribose 5′ is converted to an N‑methyluronamide.

Synthetic Utility

Although primarily employed as a bioactive tool compound, limited synthetic manipulations are feasible for probe development and SAR studies (general literature guidance):

  • Reactive handles present:

    • Aryl iodide (3‑iodobenzyl): amenable to Pd‑catalyzed cross-couplings (Suzuki–Miyaura, Sonogashira, Buchwald–Hartwig after appropriate functionalization) to append fluorophores, affinity tags, or isotopologues.
    • Purine 2‑chloro: typically inert under mild conditions in the intact nucleoside but can participate in nucleophilic substitution in highly activated settings; generally retained to preserve A3AR affinity.
    • Hydroxyl groups on ribose (protected or free depending on synthesis) allow selective derivatization if protection/deprotection strategies are used.
  • Protection strategies:

    • Silyl protection (TBDMS/TBS) on ribose hydroxyls; temporary base protection (e.g., benzoyl or isobutyryl on adenine positions in earlier synthetic steps) as per nucleoside chemistry norms.
  • Cautions:

    • The N9‑glycosidic bond can be labile under strong acid; maintain neutral to mildly basic conditions during derivatization.
    • Heavy-atom content (I, Cl) aids MS tracking but can promote photoreactions—work under subdued light.
  • Use as an analytical surrogate:

    • Serves as a structural reference in the synthesis/purification of related A3AR agonists, enabling retention-time and MS pattern benchmarking.
Target Specificity

Not applicable to this product type. This is a small-molecule ligand, not an antibody or affinity reagent with a defined clone/isotype. For biological context, literature describes 2‑Cl‑IB‑MECA as a selective agonist of the adenosine A3 receptor (A3AR), but no item-specific target-binding data are provided here. Refer to CoA or primary literature for quantitative selectivity profiles.

Häufig gestellte Fragen

How is this product shipped?
This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.
What is the purity of this product, and how is it determined?
This product is supplied at ≥98% purity, determined by HPLC. Lot-specific values are stated on the Certificate of Analysis.
What is Moligand??
Moligand? is one of Aladdin Scientific's premium product lines, formulated for high-purity applications across multiple workflows. Compared to standard grades in the same workflow, Moligand? products typically offer tighter specifications, more rigorous QC, and stronger lot-to-lot consistency.
How should this product be stored?
Store at ?20 °C, protected from light. The material is light-sensitive — keep it in its original opaque or amber container.
What are the CAS number, molecular formula and molecular weight?
The CAS Number is 163042-96-4, the molecular formula is C18H18ClIN6O4, and the molecular weight is 544.73 g/mol. InChIKey IPSYPUKKXMNCNQ-PFHKOEEOSA-N.
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

Dürfen wir Sie über Rabattaktionen informieren?

Später erinnern

Vielen Dank! Bitte überprüfen Sie Ihren E-Mail-Posteingang, um zu bestätigen.

Hoppla! Benachrichtigungen sind deaktiviert.